文献速递血液透析通路

经皮与手术创建的前臂近端动静脉瘘长期结果的比较研究

Long Term Results of a Comparative Study of Percutaneous and Surgically Created Proximal Forearm Arteriovenous Fistulae.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-01-23

这项回顾性单中心比较效果研究分析了2017年9月至2023年9月创建的217例经皮动静脉瘘(61例WavelinQ和156例Ellipsys)与158例手术动静脉瘘,比较技术成功、成熟、通畅性、首次使用时间、再干预和并发症。结果显示手术动静脉瘘在部分结局更优,而经皮动静脉瘘(尤其Ellipsys)在另一些结局更优,手术动静脉瘘的血液透析通路诱导远端缺血更高但吻合口近端狭窄更低。

要点

  • 手术动静脉瘘和Ellipsys技术成功率均为100%,WavelinQ为93.4%(p < .001)。
  • 四週成熟率Ellipsys 78.6%、手术动静脉瘘79.7%高于WavelinQ 64.9%(p = .042)。
  • 首次穿刺中位时间Ellipsys 57天最短,手术动静脉瘘73天,WavelinQ 98.6天最长(p = .048)。

核心结论

  • 研究表明所有通路类型均可提供长期功能性血液透析通路,手术动静脉瘘在某些结局领域表现更好,而经皮动静脉瘘(尤其Ellipsys)在另一些领域更好。
  • 手术动静脉瘘的血液透析通路诱导远端缺血发生率更高,但吻合口近端狭窄发生率更低。
  • 研究结果强调个性化血管通路规划的重要性,需权衡即刻手术结局与长期功能。

研究设计与样本

  • 回顾性、单中心比较效果研究,数据来自前瞻性维护数据库。
  • 纳入2017年9月至2023年9月期间接受经皮动静脉瘘或手术动静脉瘘创建的患者。
  • 共分析217例经皮动静脉瘘(61例WavelinQ和156例Ellipsys)和158例手术动静脉瘘。
  • 结局指标包括技术成功、成熟、通畅性、首次成功使用时间、再干预和并发症。

主要发现

  • 技术成功率:手术动静脉瘘100%,Ellipsys 100%,WavelinQ 93.4%(p < .001)。
  • 四週成熟率:Ellipsys 78.6%,手术动静脉瘘79.7%,WavelinQ 64.9%(p = .042)。
  • 首次穿刺中位时间:Ellipsys 57天,手术动静脉瘘73天,WavelinQ 98.6天(p = .048)。
  • 平均随访654天(四分位距164,1049天;范围0 - 2061天)。
  • 初级通畅性手术动静脉瘘高于经皮动静脉瘘;与手术动静脉瘘相比,WavelinQ的初级通畅性丢失风险比HR为1.50,Ellipsys为1.42(p = .045)。

临床怎么用

  • 原文未据此给出推荐,结论强调个性化血管通路规划,权衡即刻手术结局与长期功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This retrospective, single centre, comparative effectiveness study aimed to compare the long term outcomes of percutaneous arteriovenous fistula (pAVF) and surgically created arteriovenous fistula (sAVF) created in the proximal forearm for haemodialysis access. METHODS: Data were reviewed from a prospectively maintained database on patients who underwent pAVF or sAVF creation from September 2017 to September 2023. A total of 217 pAVFs (61 WavelinQ and 156 Ellipsys) and 158 sAVFs were analysed. Outcome measures included technical success, maturation, patency, time to first successful use, re-interventions, and complications. RESULTS: Technical success was 100% for sAVF and Ellipsys, and 93.4% for WavelinQ (p < .001). Maturation at four weeks was higher in Ellipsys (78.6%) and sAVF (79.7%) groups than in WavelinQ (64.9%) (p = .042). Median time to first cannulation was shortest for Ellipsys (57 days), followed by sAVF (73 days), and longest for WavelinQ (98.6 days) (p = .048). Mean follow up was 654 days (interquartile range 164, 1049 days; range 0 - 2061 days). Primary patency was higher in sAVFs than in pAVFs. The Cox proportional hazard ratio (HR) for loss of primary patency was 1.50 for WavelinQ and 1.42 for Ellipsys compared with sAVF (p = .045). Secondary patency was statistically significantly lower for WavelinQ (HR 2.76; p < .001), but not for Ellipsys (HR 0.74; p = .33). Haemodialysis access induced distal ischaemia (HAIDI) was more common in the sAVF group with nine events (5.7%) compared with one for the Ellipsys (0.6%; p = .008). Re-intervention rates per patient year were comparable across groups (0.60 vs. 0.61 vs. 0.69 for sAVF, WavelinQ, and Ellipsys, respectively). CONCLUSION: This study indicates that while all access types can provide long term functional haemodialysis access, sAVFs perform better in some outcome domains and pAVFs (particularly Ellipsys) in others, with sAVFs showing higher rates of HAIDI, yet lower rates of juxta-anastomotic stenosis. The findings underscore the importance of personalised vascular access planning, weighing immediate procedural outcomes against long term functionality.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Shahverdyan R, Mehta TI, Inston N, et al. Long Term Results of a Comparative Study of Percutaneous and Surgically Created Proximal Forearm Arteriovenous Fistulae. Eur J Vasc Endovasc Surg. 2025. PMID: 39863051. doi:10.1016/j.ejvs.2025.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。